This article is more than 5 years old. Information may no longer be current.
Secukinumab yielded improvements for PsA through 2 years
Click Here to Manage Email Alerts
In patients with active psoriatic arthritis, secukinumab yielded continued improvements in signs, symptoms and multiple clinical domains through 2 years of therapy, according to data from the FUTURE 2 study.
In the ongoing, level 1 study, researchers evaluated 397 patients with active psoriatic arthritis (PsA) and were randomized 1:1:1:1 to treatment with placebo or subcutaneous secukinumab at doses of 300 mg, 150 mg or 75 mg at baseline. Patients received the treatment at baseline, at weeks 1, 2, 3 and 4, and every 4 weeks thereafter. At week 16, depending on treatment response, patients in the placebo group were re-randomized to receive subcutaneous secukinumab 300 mg or 150 mg every 4 weeks. Patients classified as non-responders to placebo were switched at week 16, while placebo responders were re-randomized at week 24. Primary efficacy endpoint was the percentage of patients attaining ACR20 response at week 24.
At week 24, the ACR20 response rates were 69.4% in the 300-mg group, 64.4% in the 150-mg group and 50.3% in the 75-mg group. At week 104, the ACR50/70 response rates were as follows: secukinumab 300-mg group, 50.6%/33.1%; secukinumab 150-mg group, 36%/23.1%; and secukinumab 75-mg group, 28.2%.14.9%. Also at week 104, PASI 75/90 response rates were as follows: secukinumab 300-mg group, 79.5%/69.6%; secukinumab 150-mg group, 73.3%/52.5%; and secukinumab 75-mg group, 58.4%/33.7%. The efficacy of the drug extended across several clinically relevant domains of PsA outcomes, including DAS28-CRP, resolution of dactylitis and enthesitis, and improvements in SF-36 physical component score and health-related quality of life disability index scores, which were maintained through week 104. These sustained responses were independent of prior anti-TNF-alpha use. Throughout the study, the incidence, type, and severity of adverse events remained stable.
“Secukinumab provided sustained improvements at 2 years across multiple clinical domains, including joint and skin, dactylitis and enthesitis, improved physical functioning and [quality of life] QoL in patients with active PsA,” the researchers wrote. “The safety profile of secukinumab showed no new or unexpected safety signals through 2 years of treatment.” -by Jennifer Byrne
Disclosure: Please see the full study for a list of relevant disclosures.
Collapse
McInnes IB, et al. Rheumatology.2017; https://doi.org/10.1093/rheumatology/kex301
Click Here to Manage Email Alerts